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Abstract
RECQL4mutations are associated with Rothmund Thomson Syndrome (RTS), RAPADI-
LINO Syndrome and Baller-Gerold Syndrome. These patients display a range of benign
skeletal abnormalities such as low bone mass. In addition, RTS patients have a highly in-
creased incidence of osteosarcoma (OS). The role of RECQL4 in normal adult bone devel-
opment and homeostasis is largely uncharacterized and how mutation of RECQL4
contributes to OS susceptibility is not known. We hypothesised that Recql4 was required for
normal skeletal development and both benign and malignant osteoblast function, which we
have tested in the mouse. Recql4 deletion in vivo at the osteoblastic progenitor stage of dif-
ferentiation resulted in mice with shorter bones and reduced bone volume, assessed at 9
weeks of age. This was associated with an osteoblast intrinsic decrease in mineral apposi-
tion rate and bone formation rate in the Recql4-deficient cohorts. Deletion of Recql4 in ma-
ture osteoblasts/osteocytes in vivo, however, did not cause a detectable phenotype. Acute
deletion of Recql4 in primary osteoblasts or shRNA knockdown in an osteoblastic cell line
caused failed proliferation, accompanied by cell cycle arrest, induction of apoptosis and im-
paired differentiation. When cohorts of animals were aged long term, the loss of Recql4
alone was not sufficient to initiate OS. We then crossed the Recql4fl/fl allele to a fully pene-
trant OS model (Osx-Cre p53fl/fl). Unexpectedly, theOsx-Cre p53fl/flRecql4fl/fl (dKO) ani-
mals had a significantly increased OS-free survival compared toOsx-Cre p53fl/fl orOsx-Cre
p53fl/flRecql4fl/+ (het) animals. The extended survival was explained when the Recql4 sta-
tus in the tumors that arose was assessed, and in no case was there complete deletion of
Recql4 in the dKO OS. These data provide a mechanism for the benign skeletal phenotypes
of RECQL4mutation syndromes. We propose that tumor suppression and osteosarcoma
susceptibility are most likely a function of mutant, not null, alleles of RECQL4.
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Author Summary
Rothmund Thomson Syndrome (RTS), RAPADILINO Syndrome and Baller-Gerold Syn-
drome are very rare human syndromes associated with mutations in RECQL4. RECQL4 is
important for controlling how cells divide and for preventing genome damage. Patients
with RECQL4 mutations have problems with bone formation and a low bone mass, similar
to osteoporosis. RTS patients have a highly increased risk of developing bone cancer (oste-
osarcoma). The role of RECQL4 in normal bone development and osteosarcoma forma-
tion is largely unknown. We have used mouse models to understand the specific role of
Recql4 in bone development. Mice with Recql4 removed specifically from their bone cells
have shortened bones and a reduced rate of bone formation. Therefore, RECQL4 is essen-
tial for normal bone development. Interestingly, the animals with no Recql4 in bone cells
did not develop osteosarcoma. Using mouse models of osteosarcoma, we observed delayed
cancer formation when Recql4 was also deleted. Further analysis demonstrated that bone
cancer could not arise from Recql4 null cells even with concurrent p53 deletion. These
studies clarify the role of RECQL4 in both normal and malignant bone biology and suggest
that RECQL4 mutations that cause osteosarcoma most likely result in proteins with re-
duced, but not absent, function.
Introduction
Rothmund-Thomson syndrome (RTS), RAPADILINO Syndrome and Baller-Gerold Syn-
drome are rare autosomal recessive disorders that are associated with mutations in the DNA
helicase RECQL4. RECQL4 belongs to a family of RecQ helicases that are important in the reg-
ulation of DNA repair and replication, and constitutes five human members: BLM,WRN,
RECQL4, RECQ1 and RECQ5 [1]. Along with RECQL4,WRN and BLM are also associated
with human hereditary disorders involving both skeletal defects and cancer predisposition [1].
Mutations inWRN cause Werner Syndrome, in BLM Bloom Syndrome and when RECQL4 is
mutated RTS and related syndromes arise [1,2]. Abnormalities in skeletal development are a
defining feature of the human disorders associated with mutations in RecQ helicases, such as
short stature, osteoporosis, low bone mass and polydactyly [3–6]. In addition to the develop-
mental phenotypes shared across RecQ helicase mutation kindreds, RTS patients are predis-
posed to develop osteosarcoma (OS) [6,7]. However, neither the role of RECQL4 in osteoblast
biology nor the influence of RECQL4mutations in the initiation and maintenance of OS have
been defined.
OS is the most common primary tumor of bone and it is currently treated with chemothera-
py and surgical resection [8–10]. It presents bi-modally, primarily in children and teenagers
with a second incidence after the age of 70 [11]. Recent data has begun to shed light on the
complex genetics of conventional OS [12], and have revealed that OS is characterised by multi-
ple somatic mutations and chromosomal aberrations [13]. Strikingly, with the exception of
TP53, there are few highly recurrent somatic alterations [12]. These data highlight that OS is a
disease most broadly characterised by a tolerance of genomic instability and mutation burden.
Whilst these studies have begun to provide information about the landscape of the OS genome,
the initiating events that enable OS formation are less clear. Conversely, human familial cancer
syndromes have provided great insight into the genetic initiating events of OS.
Three familial syndromes are strongly associated with a predisposition to OS: Li-Fraumeni
syndrome (TP53mutations), hereditary retinoblastoma (RB1mutations) and RTS. Indeed,
mutations in the TP53 occur in>90% of conventional OS, and this observation is supported
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by murine OS models that demonstrate a p53 pathway mutation dependence [12,14–18]. In
contrast to both TP53 and RB1 pathways, mutations in RECQL4 have not been observed in
sporadic OS. Indeed, elevated levels of RECQL4 have been reported in sporadic OS, a result po-
tentially confounded by the close genomic linkage of the RECQL4 locus withMYC, which is
amplified in many OS [19,20]. Despite the apparently contradictory nature of the data, about
30% of RTS patients with deleterious RECQL4mutations develop OS [7]. RTS associated muta-
tions in RECLQ4 are notable in that they display an unusually high proportion of mutations
that impact on splicing, possibly resulting from the presence of numerous short introns, and
that mutations spare the N-termial region of protein [21–23]. A primary function of RECQL4
is thought to be mediated by its ATP-dependent helicase RecQ domain, and RTS associated
mutations cluster to this region [21]. These clinical observations raise several important ques-
tions about the role of RECQL4 in osteoblast biology and tumorigenesis: firstly, what is the
function of RECQL4 that leads to the benign skeletal defects observed in RTS patients? Second-
ly, what role does RECQL4 play in OS initiation and maintenance?
Previous attempts to generate Recql4 deficient mice have yielded three non-conditional al-
leles with divergent phenotypes. The first reported allele deleted exons 5–8, resulting in early
embryonic lethality [24]. A second allele, generated by an in-frame deletion of exon 13, encod-
ing part of the RecQ helicase domain, resulted in 95% of the mice dying within two weeks of
birth [25]. The small proportions of viable homozygous mutants displayed severe growth retar-
dation, but were not reported to develop OS. The third allele replaced part of exon 9 through to
13 with a PGK-Hprt mini gene cassette [26]. Although most homozygous mutant mice were vi-
able, a small proportion displayed skeletal defects such as polydactyly and shorter limbs. These
mice also developed cancers including OS, at low penetrance (5% incidence of cancer overall,
40% of cancers were OS (n = 2 animals)). The latter two alleles were both characterised by the
presence of aberrant Recql4 transcripts within the cells, which potentially resulted in the gener-
ation of C-terminal truncated proteins. These limitations confound the understanding of the in
vivo role of Recql4 in both normal development and tumor formation.
We recently described a conditional murine Recql4 allele generated by flanking exons 9 and
10 with loxP elements [27]. This region was selected to enable inactivation of the helicase do-
main and reflect the preponderance of mutations in this region in humans with RTS. In the
mouse, exon 9 encodes the start of the ATP dependent RecQ helicase domain. Germ-line dele-
tion of exons 9 and 10 resulted in embryonic lethality prior to E10.5, most similar to the pheno-
type reported with deletions of exons 5–8. Somatic deletion of Recql4 in adult mice resulted in
the rapid development of a fully penetrant bone marrow failure-like syndrome and death of
the Recql4 deficient animals [27]. This model precluded analysis of the role of Recql4 in skeletal
development and OS. We have now used targeting deletion of this conditional allele within the
osteoblast lineage to understand the requirement for Recql4 in normal skeletal homeostasis
and OS development.
Results
Generation of osteoblast specific Recql4 deficient mice
As a result of the embryonic lethality of germ-line Recql4-/- animals and the lethal, non-skeletal
phenotype upon somatic deletion of Recql4 in adult mice [27], we moved to a lineage restricted
deletion model to examine the role of Recql4 in skeletal development and malignancy. To
achieve osteoblast-restricted deletion of Recql4, we crossed the Recql4fl/fl mice with two Cre
strains active at distinct stages of osteoblast development (Fig 1A). Firstly, we used the Oster-
ix1-GFP::Cre (Osx-Cre) transgenic mouse where Cre is active in the proliferative osteoblast
progenitor populations [28]. Secondly, to delete Recql4 in the committed mature osteoblast/
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osteocyte population we used the Dentin matrix protein 1-Cre (Dmp1-Cre) transgenic line
[29]. In both cases, the Rosa26-eYFP strain that reports Cre activity through the expression of
eYFP was included to allow for tracing and isolation of Cre exposed cells [30]. The distinct spa-
tiotemporal expression of Osx and Dmp1 allows for in vivo assessment of the requirement for
Recql4 in osteoblast lineage development.
Reduced skeletal growth inOsx-Cre Recql4fl/flmice
It had previously been reported that heterozygous germ-line Recql4mutant mice displayed a
skeletal phenotype, although their human counterparts (parents/siblings of RTS patients) do
not present with any apparent skeletal changes [3,27,31]. We assessed skeletal parameters by
micro-computed tomography (μCT) in male germ-line exon 9–10 deficient Recql4+/- mutants.
Fig 1. Deletion of Recql4 in osteoblast precursors results in dwarfism. (A) Diagram of Cre-mediated Recql4 deletion. (B) Representative photograph of
maleOsx-CreRecql4+/+ and Recql4fl/flmice. (C) Gross body weights of maleOsx-CreRecql4mice. n 7 for both genotypes. Data presented asmean±SEM.
**P<0.01 compared withRecql4+/+, t-test.
doi:10.1371/journal.pgen.1005160.g001
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We observed no significant changes in any bone parameter, nor did we observe any phenotype
(malignant or otherwise) in the Recql4+/- mice upon extended aging.
We next investigated the effects of Recql4 deletion from the pre-osteoblast populations
using Osx-Cre on normal skeletal development. Only male mice were assessed for all genotypes
to exclude any influence of sex differences in bone structure, and all controls in these studies
are Osx-Cre+ Recql4+/+ to control for the effects of the transgene alone on bone [32,33]. While
Osx-Cre Recql4fl/+ had no phenotype and were no different to Osx-Cre Recql4+/+ controls, Osx-
Cre Recql4fl/flmice were smaller than Osx-Cre Recql4+/+ control littermates as evidenced by a
significantly lower body weight (Fig 1B and 1C). Osx-Cre Recql4fl/fl mice had shorter tibia at 9
weeks of age (Fig 2A and 2B), while there was less mineralized bone within the long bones
when assessed by von Kossa staining (Fig 2C). Although efficient genomic recombination of
Recql4 in adult tissues was only observed in bone tissue (Fig 2D), we had previously observed a
selection against stable deletion of Recql4 in hematopoietic cells [27]. To ascertain if stable dele-
tion was occurring in osteoblast precursors, we isolated hematopoietic and vascular marker
negative (CD45-Lin-CD31-) cells from the collagenase digested compact long bones. These were
fractionated into eYFP positive and negative populations, distinguishing cells that have expressed
Cre during development and would be expected to have Recql4 recombined (eYFP+ve), from
Cre negative cells. Genomic DNA was isolated from each population fromOsx-Cre Recql4fl/fl
and Osx-Cre Recql4+/+ control littermates. Essentially complete deletion of exons 9 and 10 was
observed in the eYFP+ve fraction from the Osx-Cre Recql4fl/fl (Fig 2E and 2F). This demonstrates
that stable deletion was achieved with no recovery of non-deleted/heterozygous cells to confound
the interpretation of the phenotype. Nonetheless, during these cell isolations a significantly lower
proportion of eYFP positive phenotypic osteoblastic cells was noted in the Osx-Cre Recql4fl/fl
mice compared to controls (Fig 2E and 2F).
The effect of Recql4 deletion from the early stages of osteoblast differentiation on skeletal ar-
chitecture was assessed by μCT analysis of the trabecular bone within the secondary spongiosa
and the diaphyseal cortical bone of the tibia. Qualitative assessment of pseudo-colored volume-
rendered images of Osx-Cre Recql4fl/fl tibiae showed an apparently lower density with less tra-
becular bone (Fig 3A). This trabecular phenotype presented with a 17% reduction in bone vol-
ume as a proportion of total volume (BV/TV) (Fig 3B) compared to controls. Correspondingly,
there was a 16% decrease in trabecular number (Tb.N) and a 17% increase in trabecular separa-
tion (Tb.Sp.), with no change in trabecular thickness (Tb.Th) (Fig 3B). We further character-
ized the bone structure and remodeling by histomorphometry within the proximal secondary
spongiosa of the tibia. The low trabecular bone mass observed by μCT was associated with sim-
ilar, but not statistically significant reductions in total bone volume and trabecular number,
and increased trabecular separation in this second site (S1A Fig). There was no change in oste-
oid surface, thickness or volume, nor in the numbers of osteoblasts (N.Ob/B.Pm) or osteoclasts
(N.Oc/B.Pm) per unit of bone perimeter (S1C Fig). Despite this, dynamic histomorphometry
showed a significant 36% and 42% decrease in both mineral apposition rate (MAR) and bone
formation rate (BFR/BS) respectively inOsx-Cre Recql4fl/flmice, with no change in the mineral-
ising surface per bone unit surface (MS/BS) compared to control mice (Fig 3C). Within the cor-
tical bone, Osx-Cre Recql4fl/fl tibiae showed 10% and 14% reduction in cortical thickness (Ct.
Th) and cortical bone area (Ct.Ar) respectively, with slight, but non-significant decrease in cor-
tical cross-sectional bone area (Tt.Ar) and cortical bone area fraction (Ct.Ar/Tt.Ar) in the
Recql4 deficient animals (Fig 3D and 3E). Collectively, these data demonstrate an essential re-
quirement for Recql4 in osteoblast function.
Given the known role of the bone marrow microenvironment in regulating hematopoietic
homeostasis, we also assessed hematopoiesis in the Osx-Cre Recql4fl/fl and Osx-Cre Recql4+/+
littermates. We detected no differences in peripheral blood composition nor bone marrow
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Fig 2. Osx-CreRecql4fl/flmice have reduced bone length. (A) X-ray of tibia frommaleOsx-Cre Recql4+/+ and Recql4fl/flmice. (B) Measurement of tibial
length fromOsx-Cre Recql4+/+ and Recql4fl/flmice. n 9 for both genotypes. Data presented as mean±SEM. **P<0.01 compared with Recql4+/+, t-test. (C)
Representative photo of Von Kossa staining of 9 week oldOsx-Cre Recql4 tibiae. (D) Detection of Recql4 genomic excision in various tissues fromOsx-Cre
mice. (E) Percentage of FACS-sorted osteoblastic cells (Lin- CD31- CD51+ Sca1-) fromOsx-Cre Recql4mice. Data presented as mean±SEM. *P<0.05
compared with Recql4+/+, t-test. (F) Osteoblastic cells fromOsx-Cre R26YFP Recql4mice were sorted into eYFP+ve and eYFP-ve fractions prior to genomic
DNA extraction and assessment of Recql4 genomic excision.
doi:10.1371/journal.pgen.1005160.g002
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Fig 3. Osx-CreRecql4fl/flmice have a low bonemass. (A) Representative images of reconstructed trabecular region of the proximal tibial secondary
spongiosa (top) and color-coded quantitative mineralization images (bottom) frommaleOsx-Cre Recql4+/+ and Recql4fl/flmice. (B) Trabecular bone volume
(BV/TV), trabecular separation (Tb.Sp), trabecular number (Tb.N), trabecular thickness (Tb.Th) ofOsx-Cre Recql4 tibiae. n 8 for both genotypes. (C)
Mineralization apposition rate (MAR), mineralizing surface per unit bone surface (MS/BS) and bone formation rate per unit bone surface (BFR/BS) from the
Recql4 Is Required for Normal Osteoblast Development
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hematopoiesis in the osteoblast restricted Recql4-deficient animals (S2A–S2C Fig). Recql4 defi-
cient osteoblasts are able to support hematopoiesis normally.
The deletion of Recql4 in mature osteoblastic cells did not result in a
bone phenotype
Given the striking effect of Recql4 deletion from pre-osteoblast stages on skeletal development,
we sought to determine what impact deletion of Recql4 would have when restricted to mature
osteoblasts and osteocytes. To this end, we used the Dmp1-Cre transgenic line [29,34] (Fig 4A).
Efficient genomic deletion of Recql4 was seen in bone tissues, however unlike Osx-Cre, we also
observed genomic recombination of Recql4 in muscle tissue, as previously reported for this Cre
line (Fig 4B) [35]. Littermate male Dmp1-Cre Recql4+/+ and Dmp1-Cre Recql4fl/flmice were
comparable in weight and overall size (Fig 4C) and tibial lengths were the same between the co-
horts (Fig 4D). Analysis by μCT of the trabecular and cortical bone regions of the tibia did not
demonstrate any differences in those parameters assessed (Fig 4E and 4F). Collectively, the
data indicate that although Recql4 is required in the proliferating and differentiating osteoblas-
tic population, it is not required in mature osteoblast and osteocyte populations to maintain
bone homeostasis.
Depletion of Recql4 resulted in inhibition of cell proliferation and
osteogenic differentiation
We initially planned to use FACS-purified, eYFP positive osteoblastic cells from the Osx-Cre
Recql4+/+ and Osx-Cre Recql4fl/flmice to delineate the role of Recql4 (Fig 2E). However, the low
yields and very poor proliferation of the eYFP positive cells from Osx-Cre Recql4fl/fl cells ren-
dered them unsuitable for further analysis [36,37]. We therefore utilized primary long bone os-
teoblastic cells from Rosa26-CreERT2 Recql4mice [27]. Tamoxifen (4-OHT) was added to
these cultures for up to 21 days to activate Cre mediated deletion of Recql4 and cell prolifera-
tion assays were performed during the first and third week.
Rosa26-CreERT2 Recql4fl/+ cells (control, referred to as Recql4Δ/+) proliferated comparably
to non-tamoxifen treated cultures for the entire culture period (21 days). When assessed 7 days
after the addition of tamoxifen, gene recombination was apparent in the Rosa26-CreERT2
Recql4fl/fl cells (homozygous deletion of Recql4, referred to as Recql4Δ/Δ), but only slightly
more than 60% of the floxed allele had been deleted. Between days 2 and 7, there was no differ-
ence in proliferation rates between Recql4Δ/+ and Recql4Δ/Δ cells (Figs 5A, 5B and S3). At day
14 after tamoxifen addition, recombination of the Recql4 allele had increased to closer to 80%
in both sets of genotypes (Figs 5B and S3). At this time, the tamoxifen-treated Recql4 Δ/Δ pri-
mary osteoblasts failed to proliferate (Fig 5A), while non-tamoxifen treated Recql4Δ/Δ cells
proliferated similarly to controls (Recql4Δ/+ ± tamoxifen). The more complete the genomic de-
letion of Recql4, the more profound the proliferation arrest was apparent (Figs 5B and S3).
These studies demonstrate a requirement for Recql4 in normal osteoblast expansion, and sug-
gest that the in vivo phenotype may be attributed to the impaired proliferation of Recql4 defi-
cient osteoblastic cells.
To allow for a more detailed analysis of osteoblast proliferation and differentiation, we
moved to a short hairpin RNA (shRNA) approach. We utilized the Kusa4b10 murine cell line
dynamic histomorphometric analysis of the proximal tibial secondary spongiosa. n = 5–6 for both genotypes. (D) Representative images of reconstructed
cortical bone with colour-coded quantitative mineralisation fromOsx-Cre Recql4+/+ and Recql4fl/flmice. (E) Cortical thickness (Ct.Th), cortical bone area (Ct.
Ar), total cortical cross-sectional bone area (Tt.Ar) and cortical bone area fraction (Ct.Ar/Tt.Ar) ofOsx-Cre Recql4 cortical tissue. n 8 for both genotypes.
Data presented as mean±SEM. *P<0.05, compared with Recql4+/+, t-test.
doi:10.1371/journal.pgen.1005160.g003
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which has the capacity to differentiate into osteoblastic or adipogenic lineages [38]. We identi-
fied one shRNA (#5254), amongst numerous screened, which reduced the expression of Recql4
at both the transcript and protein levels in Kusa4b10 cells (Figs 5C, 5D, S4A, and S4B). Con-
trols were either a second shRNA against Recql4 (#5255) that did not reduce transcript levels,
or a luciferase-targeting shRNA.
The knockdown of Recql4 caused a striking phenotype in the Kusa4b10 cells. In particular,
the cells displayed a ‘flattened’ morphology as compared to the controls, and proliferation was
completely blocked (Fig 5E and 5F). The cell surface phenotype of the knockdown cells
changed, with a reduction in the expression of Sca-1, a marker of proliferation, but no change
in CD51 expression (Fig 5G) [39,40]. Depletion of Recql4 led to a 2-fold increase in apoptosis,
as evidenced by increased Annexin V staining (Fig 5I). The most pronounced difference, how-
ever, became apparent when we assessed the cell cycle distribution of Recql4 knockdown cells.
EdU pulse-labelling demonstrated a near complete absence of DNA replication or S-phase
populations in the knock-down cells compared to controls (Fig 5H). In contrast to recent re-
ports that assessed the acute depletion of RECQL4 with shRNA or siRNA [41], we did not ob-
serve an increase in senescence associated ß-galactosidase positive cells in Recql4-knockdown
cultures compared to control infected cultures when assessed at similar time points post knock-
down (S4C and S4D Fig). Taken together with the primary osteoblast analysis, these Recql4 de-
pletion leads to a profound proliferation arrest and an elevated level of apoptosis without
appreciable effects on senescence.
To determine if the loss of Recql4 affected osteoblast differentiation in addition to prolifera-
tion, control and knock-down Kusa4b10 cells were placed under osteoblastic differentiation
conditions. To account for the reduced proliferative potential of the Recql4 depleted cells, the
cells were seeded to be fully confluent at the start of differentiation. The knockdown of Recql4
led to a near complete failure in mineralization, as assessed by alizarin red staining, over a 21
day differentiation time-course (Fig 5J). All wells were visually confirmed to have a confluent
sheet of cells, yet the Recql4 depleted cells were unable to mineralise under these assay condi-
tions. Profiling of markers of osteoblastic maturation and differentiation by qPCR revealed
that whilst Runx2 expression was not affected, all markers of osteoblast differentiation down-
stream of this were significantly reduced in Recql4 knockdown cells, consistent with the failure
to mineralize (S4E Fig). These data suggest that Recql4 is not only required for normal prolifer-
ation of osteoblast precursors but also contributes to their maturation in vitro, a result consis-
tent with the low bone formation rate in the presence of unchanged osteoblast numbers in the
Osx-Cre Recql4fl/fl mice.
The concurrent loss of p53 does not rescue Recql4 deficient osteoblast
proliferation
Recql4 has been proposed to interact with p53, which has been reported to inhibit osteoblast pro-
liferation [15,42]. To explore the relationship between the two genes, we treated primary long
bone osteoblastic cells from R26-CreERT2 Recql4fl/flp53fl/flmice with tamoxifen and subjected them
to proliferation assays as described previously (Fig 6A). After 14 days, the Recql4+/+p53Δ/Δ cells
displayed increased proliferation compared to its non-tamoxifen treated isogenic counterpart. In
Fig 4. Dmp1-CreRecql4fl/flmice do not display a bone phenotype. (A) Schematic of generatingDmp1-CreRecql4+/+ and Recql4fl/flmice. (B) The
assessment of Recql4 genomic excision in various tissues fromDmp1-Cre mice. (C) Gross body weights of maleDmp1-Cre Recql4 mice. n = 4 for Recql4+/+,
n = 6 for Recql4fl/fl. (D) Measurement of tibiae from Dmp1-CreRecql4+/+ and Recql4fl/flmice. n = 4 forRecql4+/+, n = 8 forRecql4fl/fl. (E) Trabecular bone volume
(BV/TV), trabecular separation (Tb.Sp), trabecular number (Tb.N), trabecular thickness (Tb.Th) ofDmp1-Cre Recql4 tibiae. (F) Cortical thickness (Ct.Th),
cortical bone area (Ct. Ar), total cortical cross-sectional bone area (Tt.Ar) and cortical bone area fraction (Ct.Ar/Tt.Ar) ofDmp1-CreRecql4 cortical tissue. Data
from 9 week old male mice; n = 4 forRecql4+/+, n = 8 for Recql4fl/fl. Data presented asmean±SEM. *P<0.05 compared with Recql4+/+, t-test.
doi:10.1371/journal.pgen.1005160.g004
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contrast, concurrent and equally efficient, deletion of both Recql4 and p53, resulted in proliferation
kinetics similar to the Recql4Δ/Δ single mutants (Figs 4A and 6B–6D). This demonstrated that the
loss of p53 is insufficient to rescue the proliferative defect of Recql4Δ/Δ osteoblasts in vitro.
Fig 5. The depletion of Recql4 in vitro causes proliferation arrest. (A) Primary long bone osteoblastic cells were derived from Rosa26-CreERT2 Recql4
mice treated with tamoxifen and subjected to proliferation assays. n = 3 independent cultures per genotype. (B) The assessment of Recql4 genomic excision
from tamoxifen-treated osteoblastic cells. n = 3 independent cultures per genotype. (C) Immuno-blot of Recql4 protein levels from Kusa4b10 cells, with α-
tubulin as a loading control. (D) Quantitative real-time PCR (qPCR) analysis of Recql4 from Kusa4b10 cells. Relative gene expression levels were
normalised to the expression of Hprt. n = 4 biological replicates. (E) Light microscopic images of control (shRNA-Luc) and sh-Recql4 (#5254) Kusa4b10 cells
(200Xmagnification). (F) shRNA-Luc and sh-Recql4 (#5254) cells were seeded in 6-well plates and cell counts were performed at 24hr intervals. n = 4
independently infected cultures. (G-I) Control (shRNA-Luc) and sh-Recql4 (#5254) cells were seeded 24 hrs prior to flow cytometry analysis, and were
stained with antibodies against CD51 and Sca1 (G), EdU and 7AAD (H), and Annexin V and 7AAD (I). Representative FACS plots shown on the top,
percentages of stained cells summarised in bar graphs at bottom. n = 3–4 biological replicates. (J) shRNA-Luc and sh-Recql4 (#5254) cells were subjected to
osteogenic differentiation and stained with Alizarin Red. Representative photos are shown at top, while the quantification of eluted Alizarin Red dye is shown
at the bottom. n = 3 biological replicates; All graphical data presented as mean±SEM. *P<0.05, **P<0.01, ***P>0.0005, ****P>0.00001 compared with
control, t-test or 2-way ANOVA.
doi:10.1371/journal.pgen.1005160.g005
Fig 6. Concurrent loss of p53 does not modify the Recql4 phenotype. (A) and (B): Primary long bone
osteoblastic cells were derived from R26-CreERT2 Recql4 p53mice. They were then treated with
tamoxifen and subjected to proliferation assays. n = 3–4 independent cultures per genotype; Data
presented as mean±SEM. *P<0.05, **P<0.01, ***P>0.0005, ****P>0.00001 compared with vehicle,
2-way ANOVA. (C) The assessment of p53 genomic excision from tamoxifen-treated long bone
osteoblastic cells from R26-CreERT2 Recql4 p53mice. Data presented as mean±SEM. (D) The
assessment of Recql4 genomic excision from tamoxifen-treated long bone osteoblastic cells from R26-
CreERT2 Recql4 p53mice.
doi:10.1371/journal.pgen.1005160.g006
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Osx-Cre Recql4fl/flmice do not spontaneously develop osteosarcoma
Given the high incidence of OS in RTS patients, we established cohorts of Osx-Cre Recql4+/+,
Osx-Cre Recql4fl/+ and Osx-Cre Recql4fl/flmice that were allowed to age and were monitored
for the development of cancer, particularly OS. These cohorts were followed over a 100 week
period. No animals were found with OS, irrespective of the genotype (Fig 7A and S1 Table).
Whilst we may not have a sufficiently large sample size to resolve a low incidence of OS devel-
opment within these specific cohorts, no OS has ever been observed in the Osx-Cre Recql4fl/fl
mice within our entire colony (>100 Osx-Cre Recql4fl/fl mice of various ages up to 2 years).
This demonstrates that complete deletion of Recql4 in osteoblast precursors is not sufficient to
initiate OS in the mouse at high frequency.
Increased OS-free survival inOsx-Cre p53fl/flRecql4fl/fl double knock-
outs
The only mutation to occur in all human OS is the loss or mutation of TP53 [12]. Experimen-
tally, loss of p53 from within the osteoblast lineage is sufficient to initiate OS with near com-
plete penetrance [14,17]. To determine whether deletion of Recql4 in an Osx-Cre p53fl/fl
background would accelerate OS initiation and shorten OS-free survival, we established co-
horts of Osx-Cre p53fl/flRecql4+/+, Osx-Cre p53fl/flRecql4fl/+ and Osx-Cre p53fl/flRecql4fl/flmice.
OS was observed the in Osx-Cre p53fl/flRecql4+/+ mice as expected with a median onset of 247
days (Fig 7A and S1 Table; larger comparison cohort from our colonies previously reported:
median survival time 226 days [43]). The loss of one allele of Recql4 did not significantly affect
OS-free survival time compared to the Osx-Cre p53fl/flRecql4+/+mice, consistent with the lack
of phenotype in Recql4 heterozygous animals and humans (Fig 7A and S1 Table). However,
and unexpectedly, Osx-Cre p53fl/flRecql4fl/flmice had a significantly increased OS-free survival,
with a median survival time of 346 days compared to Osx-Cre p53fl/flRecql4fl/+ controls (Fig 7A
and S1 Table).
The Osx-Cre p53fl/flRecql4fl/fl mice more frequently presented with multiple primary tumors
as compared to the Recql4 wildtype or heterozygous cohorts. The majority of the primary OS
were distributed in axial locations (eg., the rib-cage and the vertebrae). We have not observed
any non-OS tumors, such as hibernoma, in these cohorts independent of the genotype. Inter-
estingly, while there was no difference in macroscopic metastatic incidence between Recql4+/+
and Recql4fl/fl tumour-bearing mice (including comparison to larger historic cohorts within the
same facility), the Recql4fl/+mice presented with an increased metastatic incidence at autopsy
compared to either the Osx-Cre p53fl/flRecql4+/+ or Osx-Cre p53fl/flRecql4fl/flmice. Irrespective
of Recql4 status, metastatic tumors were most commonly located in the lung.
To understand if loss of Recql4 altered the biology of the OS that arose, we analysed a range
of tumor characteristics. There were no grossly apparent differences between the three cohorts
in the histology of the OS as assessed by either histology or μCT scans of primary tumors (Figs
7B, 7C and S5). Cell surface markers PDGFRa, CD51 and Sca-1 were screened on primary cell
cultures derived from tumors of the individual genotypes and there was no difference based on
Recql4 status (Fig 7D). The OS cell cultures behaved similarly when placed under differentia-
tion inducing culture conditions (Fig 7E). There were no differences in the expression of a
panel of osteoblast differentiation stage markers as assessed by qPCR (Fig 7F). Therefore, the
only appreciable differences between OS arising in the Osx-Cre p53fl/flRecql4fl/+ and Osx-Cre
p53fl/flRecql4fl/flmice was the survival time and metastatic frequency. The explanation for the
increased OS-free survival in the double knock-outs became apparent when we assessed the
status of the Recql4 allele in the OS cells. In all cases, complete genomic recombination of the
single floxed Recql4 allele was seen in the OS from Osx-Cre p53fl/flRecql4fl/+mice. In striking
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contrast, in no case did we observe complete deletion of both floxed Recql4 alleles in the Osx-
Cre p53fl/flRecql4fl/flmice (Fig 7G). This demonstrates that mutations resulting in null alleles of
Recql4 are not initiating events in OS and that loss of Recql4 does not co-operate with p53mu-
tation to initiate OS. The increased OS-free survival Osx-Cre p53fl/flRecql4fl/fl mice is most likely
a result of selective pressure to retain an intact allele of Recql4 in the tumor that arises.
Discussion
In humans, mutations of RECQL4 are associated with a series of related syndromes RTS,
RAPADILINO Syndrome and Baller-Gerold Syndrome. In common amongst these syn-
dromes, and other human disorders associated with mutations in RecQ helicases, are defects in
skeletal homeostasis leading to skeletal abnormalities including low bone mass, and in the case
of RTS, OS [1]. Here we demonstrate that Recql4 is required for the expansion and normal dif-
ferentiation of osteoblast precursor populations. In vivo we demonstrated that the deficiency of
Recql4 in Osx-Cre expressing osteoblastic cells resulted in shorter bones and reduced bone
mass (trabecular and cortical) that resulted from a reduced bone formation rate. The absence
of changes in osteoclastogenesis as assessed by histomorphometry, and hematopoiesis more
generally, indicate that the phenotype was osteoblast cell intrinsic. When deletion of Recql4
was restricted to more mature populations using Dmp1-Cre, the mice did not demonstrate a
skeletal phenotype. Therefore, Recql4 is required for the normal proliferation and expansion of
the pre-osteoblast populations, but it is dispensable for mature osteoblasts/osteocytes, includ-
ing the functions of osteocytes that regulate mineralization. At the resolution of histomorpho-
metry it is only possible to describe the nature of the cells (osteoblast lineage etc) not whether
they are still proliferative or viable, as we have described in other mutants [36]. As Osx-Cre ex-
pressing cells turn over regularly [44] it is as expected that a static view of osteoblasts per bone
surface may not yield a difference but the overall bone formation rate and amount of bone in
the entire limb are reduced. This is consistent with a quantitative rather than a qualitative de-
fect. In primary osteoblast cultures with induced deletion of Recql4 we saw normal prolifera-
tion for the first 14 days of culture and then suppressed proliferation in the Recql4Δ/Δ. This is
very similar to the phenotype we previously reported in primary B- and T-cell cultures [27]. In
keeping with a dilutional model of Recql4 function in DNA replication, as demonstrated in
Xenopus [45], cells null for the Recql4 gene proliferate normally for 2 weeks in vitro and for
multiple weeks in vivo continue to contribute to bone formation. However, once they reach
critically low levels of Recql4 protein they most likely cease proliferation and, ultimately, un-
dergo apoptosis. Concurrent deletion of p53 was not able to rescue the proliferative defect ob-
served in Recql4-deficient cells. This is consistent with the failure of p53 deletion to rescue the
lethal bone marrow failure that occurs upon widespread somatic deletion of Recql4 in adult
mice [27]. Collectively, these studies lead us to conclude that the primary physiological func-
tion of Recql4 is in cell proliferation and DNA replication [46,47].
RECQL4 has well characterized roles in several critical cellular functions including DNA
replication and genome stability [1,2,47,48]. Additional roles have been proposed based on
studies in cell culture models including regulation of senescence, interactions with the
Fig 7. The loss of Recql4 does not initiate osteosarcoma. (A) Kaplan-Meier survival plots ofOsx-Cre Recql4 (left) andOsx-Cre p53fl/fl Recql4 (right) mice.
P value calculated by Log-Rank statistical test. (B) H&E stained sections of primary OS tumors fromOsx-Cre p53fl/fl Recql4 animals of indicated genotype.
(C) Representative reconstructed μCT images of primary OS tumors fromOsx-Cre p53fl/fl Recql4fl/+ and Recql4fl/flmice. (D) Flow cytometry percentages of
tumor cells stained with CD51, Sca1 and PDGFRα. n = 3 for Recql4+/+, n = 8 for Recql4fl/+, n = 7 for Recql4fl/fl; Data presented as mean±SEM. (E)
Representative photos of Alizarin Red-stained tumor cells that were subjected to osteogenic differentiation conditions. (F) qPCR profiling ofOsx-Cre p53fl/fl
Recql4+/+, Recql4fl/+ and Recql4fl/fl tumors for the indicated genes. n = 3–4; Data presented as mean±SEM. (G) Assessment of genomic excision of Recql4
in tumor-derived cell lines. 40ng of genomic DNA was used for PCR and subjected to gel electrophoresis.
doi:10.1371/journal.pgen.1005160.g007
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mitochondria and p53 [42,49]. Our studies of osteoblast development and prior work on he-
matopoiesis are relevant to our understanding of the normal in vivo function of Recql4. The
most prominent feature of Recql4 deficiency, as opposed to hypomorphic mutation, is a failure
in cell proliferation. In the hematopoietic system, a rapid fully penetrant bone marrow failure
results from the deletion of Recql4 [27]. The concurrent deletion of p53 did not alter the he-
matopoietic failure, consistent with a primary DNA replication/S-phase cell cycle defect. We
show that in vivo deletion of Recql4 from proliferative pre-osteoblast populations, but not ma-
ture osteoblasts/osteocytes, caused a low bone mass phenotype. In primary osteoblast cultures,
loss of Recql4 led to a failure to proliferate once gene deletion had efficiently occurred. As with
hematopoiesis, p53 deletion did not rescue the proliferative failure associated with Recql4 defi-
ciency in osteoblast cultures. We conclude that there is little evidence to support a direct genet-
ic interaction between Recql4 and p53 pathways. This is supported by the recent data from Lu
and colleagues who reported mild or no genetic rescue of a Recql4 deficient phenotype in the
limb buds or growth plates by concurrent deletion of p53 [50]. The activation of p53 in Recql4
deficient cells most likely represents a secondary effect of impaired cell cycle progression and
transcription, ultimately leading to apoptosis (S5C Fig). We did not find any increase in senes-
cent cells as was recently reported in human fibroblasts infected with shRNA against RECQL4.
It is possible that the mechanism that inhibits cell proliferation is different between the two cell
types [41], but this seems less likely given the similarities observed in primary cell cultures of
hematopoietic cells and osteoblasts.
The low trabecular and cortical bone volume of Osx-Cre Recql4fl/fl mice mirrors the low
bone mass seen clinically in RTS patients [3–6]. However, unlike RTS and related patients, we
did not see evidence of additional skeletal abnormalities such as polydactyly, radial ray defects
or cleft palate as has been reported in Recql4 hypomorphic mice [26]. The low bone mass phe-
notype is conserved and the severity of the skeletal abnormalities is likely impacted by two im-
portant differences between patient and mouse model data. Firstly, in patients, the mutant
RECQL4 proteins are present in all cells throughout the body and during all stages of skeletal
development. Secondly, in the murine model, Osx-Cre does not delete Recql4 from all bone
forming cells. This results in a chimeric setting where Recql4 wild-type cells are present and
able to partially compensate for the deficiencies in bone formation that the Recql4 null cells
have. There are less Recql4-deficient cells in the bone as evidenced by the lower proportions of
eYFP positive osteoblastic cells (Fig 2E). A completely Recql4 deficient skeletal compartment
would be expected to have a more profound phenotype. Consistent with this interpretation, it
was recently reported that a more severe skeletal disturbance was achieved using Prx1-Cre to
delete Recql4 exons 5–8 [50,51]. This study was restricted to early developmental time points
due to the impaired survival of the Prx1-Cre Recql4fl/fl animals and so no analysis of adult ani-
mals was reported. Prx1-Cre deletes in the early developing limb bud mesenchymal cells and
leads to near complete deletion in the appendicular skeleton. The Prx1-Cre Recql4fl/flmice had
growth retardation and more severe limb developmental defects than those we observed with
Osx-Cre. It should be noted that the Osx-Cre model we have used was not restricted in activity
to the postnatal skeleton and is expressed throughout skeletal development. We therefore can
not exclude a contribution from developmental effects or deletion in other mesenchymal popu-
lations, such as chondrocytes, to the adult bone phenotype that we describe. Therefore, our
data and that of Lu and colleagues [50] indicate that the primary function of RECQL4 in osteo-
blast precursors is to enable the appropriate expansion of cell populations required for normal
skeletal formation. The low bone mass phenotype is consistent, albeit varying in severity,
amongst different mesenchymal targeted Cre strains and Recql4 alleles. This analysis provides
an explaination for the low bone mass that is a hallmark of RECQL4mutations in humans and
our modeling demonstrates that this intrinsic function of RECQL4 within the skeletal system.
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RTS is notable as the third familial syndrome impacted by OS, in addition to Li-Fraumeni
and hereditary retinoblastoma kindreds. However, unlike TP53 and RB1, mutations in
RECQL4 are not a common feature of sporadic OS and appear restricted to RTS-related OS. A
role of Recql4mutations in OS has not been revealed by previous mouse models because the vi-
able mutants have hypomorphic Recql4 alleles, leading to transcription of the the N-terminal
regions [25,26]. One question that arises from these observations is whether OS in RTS patients
represents the same disease as Li-Fraumeni and hereditary retinoblastoma kindred associated
OS, and more importantly, sporadic OS in human. Our analyses demonstrate that the osteo-
blastic-restricted complete loss of function Recql4 alleles are not able to initiate OS in the
mouse. Indeed, we have not seen tumor formation in Recql4 deficient animals or aged Recql4+/-
animals of any type. The absence of OS formation in skeletally restricted Recql4 null mutants
was also recently reported when Recql4 was deleted with Prx1-Cre [51]. Prx1-Cre deletes in the
early limb bud mesenchymal cells and is active earlier than the Osx-Cre that we utilized. The
results from the independent studies of an absence of OS initiation in Recql4 deficient skeletal
models suggests that the failure to initiate OS does not reflect the choice of models, but rather,
reflects the biology of Recql4 null alleles.
As RTS patients have a 30% incidence of OS this was somewhat unexpected, but not without
precedence given our previous analysis of Osx-Cre pRbfl/fl animals which also do not develop
OS despite the high rate of OS in hereditary retinoblastoma kindreds and the rate of RB1muta-
tion in conventional OS [12,17]. Unexpectedly, homozygous deletion of Recql4 delayed OS de-
velopment in a fully penetrant Osx-Cre p53fl/flmodel, directly contrasting with the acceleration
of OS development when loss of Rb was combined with p53 deletion. This observation was ex-
plained by the incomplete deletion of Recql4 in the OS that did arise in the Osx-Cre Recql4fl/fl
p53fl/flmice. The increased OS-free survival is most likely because the Osx-Cre p53fl/fl Recql4fl/fl
are unable to proliferate, a conclusion supported by our in vitro data, and the cell that ultimate-
ly gives rise to the tumor is being selected for incomplete deletion of the Recql4 locus. This is
an inefficient process. This result demonstrates that OS most likely does not arise from the
Recql4 null cells, most plausibly due to the profoundly impaired proliferation of these cells. It
further suggests that the OS initiating cells require some level, albeit low based on the analysis
of RTS patients, of RECQL4 function to enable OS initiation and maintenance [7]. The OS pre-
disposition in RTS patients is most likely accounted for by the mutation spectrum in these pa-
tients resulting in the generation of C-terminal truncated RECQL4 proteins. These alleles are
predicted to retain the essential role of RECQL4 in DNA replication, but disable RecQ helicase
dependent functions. Thus, our working hypothesis is that aneuploidy and tumor predisposi-
tion can only arise in cells retaining the Sld2-homology regions of RECQL4 where basal cell
proliferation is intact but genomic stability is compromised [46,47,52]. Therefore, together
with the present data, we conclude that the RECQL4 is not an OS tumor suppressor when the
mutation results in a null allele.
Our results demonstrate an essential, non-redundant role for Recql4 in the expansion and
proliferation of osteoblast precursors that is not required once the cells become mature osteo-
blasts. Complete null alleles of Recql4 do not initiate OS and loss of Recql4 does not potentiate
OS initiated by p53 deletion. That OS does not arise in Recql4 null cells reflects an essential
function for Recql4 in the proliferation and expansion of the cells. These studies demonstrate
that the low bone mass is a result of the loss of RECQL4 function, but tumorigenesis most likely
requires mutant RECQL4 activity. The precise function of mutant RECQL4 in OS initiation re-
mains to be defined. Collectively our study reveals that Recql4 is essential for normal skeletal
homeostasis and that the greatly elevated rates of OS in RTS patients are not recapitulated by
the complete absence of Recql4.
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Materials and Methods
Ethics statement
All animal experiments were approved by the Animal Ethics Committee of St Vincent’s Hospi-
tal, Melbourne. AEC #044/10.
Mice
Recql4fl/flmice (C57BL/6-Recql4tm2272Arte) were generated by TaconicArtemis GmbH (Cologne,
Germany); full details of the allele have been previously described [27]. Osx-Cre, DMP1-Cre,
Rosa26-eYFP and p53fl/fl animals have been previously described and were on a C57Bl/6 back-
ground [17,28,29,53]. 5-week old male mice were weighed weekly over a 4-week period. All his-
tomorphometry and microCT was done on 9 week old male mice.
Histology and histomorphometry
Tumour tissue was obtained from Osx-Cre Recql4 p53fl/fl mice, and it was fixed in 2–4% para-
formaldehyde overnight at 4°C. After embedding in paraffin, the tissue was sectioned and
stained with hematoxlyin and eosin. Pathological assessment of the tumor sections was per-
formed blinded to the sample genotype. For dynamic histomorphometry, in vivo labeling of
bone formation was performed with intra-peritoneal injection of 8-week old male mice with
alizarin (Sigma Aldrich) and calcein (Sigma Aldrich) 7 days and 2 days respectively before tis-
sue collection [54]. Tibia were fixed in 4% paraformaldehyde and embedded in methylmetha-
crylate, 5μm sections were stained with von Kossa to identify mineralized tissue and toluidine
blue for static histomorphometry [53,55]. Histomorphometric analysis was carried out in the
secondary spongiosa of the proximal tibia metaphysis (Osteomeasure, Osteometrics, Atlanta,
GA, USA) as previously described [56].
MicroCT analysis of bone parameters
Ex vivomicroCT was performed on tibiae and tumor material using the SkyScan 1076 system
(Bruker-microCT, Kontich, Belgium). Images were acquired using the following settings: 9μm
pixel size, 0.5mm aluminum filter, 50kV voltage and 100μA current, 2400 ms exposure time,
rotation 0.5°, frame averaging = 1. Images were reconstructed and analysed with SkyScan soft-
ware programs NRecon (version 1.6.3.3), DataViewer (version 1.4.4), CT Analyser (CTan, ver-
sion 1.12.0.0) and CTVox (version 2.2.0). The trabecular analysis region of interest (ROI) was
determined by identifying the start of the mineralized zone of the proximal growth plate and
calculating 16.5% of the total tibial length towards the tibial mid-shaft, where we then analysed
an ROI of 13.5% of the total tibial length. Analysis of trabecular bone structure was completed
using adaptive thresholding (mean of min and max values) in CTan with threshold set at 45–
255 for trabecular bone. Cortical analyses were performed 35% of the total tibial length distal
from the mineralized zone of the proximal growth plate, and extending for 12% of the total tib-
ial length; the threshold values for cortical bone were set to 79–255 and global thresholding al-
gorithm was used. The 3-dimensional visualization of trabecular and cortical bone was
performed with CTVox, where volume-rendered images were pseudo-colored based on grey-
scale (pixel) intensity that is reflective of bone mineralization.
Cell culture
The Kusa4b10, long-bone primary osteoblastic cells and mouse OS cell lines (no authentication
performed) were cultured in αMEM (Lonza), 10% non heat inactivated FBS (SAFC Biosci-
ences) and 1% Penicillin/Streptamycin/Glutamine (Life Technologies). OS cell cultures were
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derived by mincing tumor tissue with a scalpel. The resulting tumor homogenate was trans-
ferred to a 6 well plate and allowed to establish in standard culture conditions. Primary cultures
were passaged at 60–80% confluence with media changes every 2–3 days. The primary osteo-
blastic cells were derived from long bone tissue, cleaned and crushed lightly with a mortar-pes-
tle. The suspension was rinsed and diluted with PBS, and this process was repeated until the
majority of hematopoietic cells had been removed (solution was clear). The bone fragments
were placed in 15ml of collagenase I (3mg/ml) (Worthington), and incubated in a shaking
37°C water bath for 45 minutes. 35ml of PBS + 2% FBS was then added and the cell suspension
was sieved. The resulting population of long-bone derived cells was centrifuged at 400g for 5
minutes, the cells were resuspended in culture media and plated onto a 6-well plate. On the
next day, the 6-well plate was washed with PBS before adding fresh culture media to remove
floating debris. By 48 hours post-derivation, the cells were ready for experiments. For experi-
ments involving Rosa26-CreERT2 Recql4 cells, cultures were treated with 500nM Tamoxifen
(4-OHT, Merck) to induce Cre activity.
Cell preparations and flow cytometry
The primary long-bone osteoblastic cells from Osx-Cre Recql4mice were obtained as described
previously [43,53]. Briefly, bone fragments were crushed and colllagenase-digested in a similar
process to the derivation of these cells for in vitro experimentation. After pelleting the bone de-
rived cells, they were stained with antibodies (Hematopoietic lineage markers, CD31, CD51,
Sca1, CD45), and separated on the FACSAria cell sorter (BD Biosciences). Osteoblastic cells
(Lineage-, CD31-, CD51+, Sca1+/-) were obtained and fractionated into YFP+ and YFP-
populations.
Assessment of genomic excision
Tissues from various organs and FACS-sorted osteoblastic cells were subjected to genomic
DNA extraction as directed by the manufacturer (Isolate II genomic DNA kit, Bioline). PCR
was performed using 40ng of genomic DNA with the sequence-verified primers and conditions
(S2 Table). Following that, the PCR products were subjected to electrophoresis on 2.5% agarose
gels and visualized on the VersaDoc imaging system (Bio-Rad). The DNA bands were quanti-
tated with the ImageJ software (NIH).
shRNA
The Recql4 shRNA were in the pLKO.1 vector and were purchased from Sigma-Aldrich (S4
Table). A Luciferase shRNA plasmid was used as a negative control (S4 Table). Ecotropic lenti-
virus was generated by transient transfection of 293T cells using calcium phosphate and the
psPax2 (Addgene plasmid #12260) and pCMV-Eco Envelope plasmid (Cell Biolabs) using
standard methods. Kusa4b10 cells were infected by spinoculation in 6-well plates. The cells
were passaged onto fresh plates after 48 hours with media containing puromycin (Sigma). The
cells were used after 2 days of antibiotic selection when non infected cells had died.
Apoptosis, cell cycle and senescence analysis
shRNA infected and selected Kusa4b10 cells were harvested and seeded at 100,000 cells per
well in a 6 well plate. On the next day the cells were stained with AnnexinV-APC antibody
(eBioscience) in 1X binding buffer (0.01M HEPES, pH7.4; 0.14M NaCl; 2.5mM CaCl2,
eBioscience) for 15 mins at room temperature in the dark. The cells were then washed with 1X
binding buffer and 5μg/ml of 7AAD was added to each sample prior to flow cytometry analysis.
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Both early apoptotic (AnnexinV+/7AAD-) and late apoptotic (AnnexinV+/7AAD+) cell popu-
lations were added together to determine the total number of apoptotic cells.
For cell cycle analysis the cells were treated with 10μM EdU (Life Technologies) for 1 hour
at 37°C. Cells were then harvested, washed in PBS with 1% BSA, and fixed with 2% paraformal-
dehyde for 15 min at room temperature in the dark. The cells were washed with PBS with 1%
BSA and stored as a pellet at 4°C. Cells were processed as described by the manufacturer (EdU
labelling kit, Life Technologies) The cells were subjected to flow cytometry to assess the cellular
incorporation of EdU.
For cellular senescence 4–5 days post infection/selection, SA-ß-gal staining was performed
with Senescence ß-Galactosidase Staining Kit according to the manufacturer’s instructions
(Cell Signalling). Briefly, the cells were washed with PBS, then fixed with 2% formaldehyde and
0.2% glutaraldehyde in PBS for 15 min at room temperature. After rinsing the cells with PBS,
the fixed cells were incubated with X-gal staining solution and visualised with an inverted
microscope.
In vitro differentiation
Osteoblastic cells were seeded and cultured for 3–4 days. After the cells reached confluence, the
media was replaced with differentiation media (αMEM, 15% FBS, 50μg/ml L-ascorbic acid,
10mM beta-glycerophosphate) and thereafter changed 2 times per week. Cells were collected
on indicated days for analysis.
For mineralization the cells were washed 3 times (1x PBS), fixed with 70% ethanol for 30
mins and stored at 4°C in fixative. After washing the cells 3 times in water, they were stained
with 0.5% Alizarin Red S (Sigma Aldrich) in water for 30 mins, then 3 washes in water and a
15 min wash in 1x PBS. 1 ml of 10% Hexadecylpyridinium chloride monohydrate (CTP, Sigma
Aldrich) in DPBS was added and the plates incubated overnight at room temperature with
shaking to elute and quantitate the Alizerin Red S. Absorbance was measured on a PolarStar
Plate Reader at OD562nm.
Gene expression analysis
RNA was extracted from OS tissue as previously described [43]. RNA was also extracted from
cell lines with the Isolate II RNA kit (Bioline). cDNA was synthesised with the Tetro kit (Bio-
line) with oligo-(dT) primers. Both SYBR-green and multiplex based probe qPCR were per-
formed on the Stratagene Mx3000P machine (Agilent Technologies) with gene-specific
primers (S3 Table). The relative gene expression was normalized to the HPRT housekeeping
gene and calculated by the 2-ΔCT method.
Immunoblot
RIPA buffer extracted protein lysates from shRNA-transduced and selected Kusa4b10 cells
were quantified with the Quick-start Bradford assay (Bio-Rad), and separated on a 4–12% Bis-
Tris gel in MOPS buffer as directed by the manufacturer (Life Technologies). The gel was then
transferred onto a PVDF membrane (Merck-Millipore). The membrane was blocked with 5%
milk in TBST and incubated overnight at 4°C with the polyclonal rabbit anti-mouse Recql4 an-
tibody (GL Biochem, 1:500) and the monoclonal anti-mouse α-tubulin antibody (Sigma,
1:5000) as previously described [27]. Subsequently, the blot was probed with horseradish per-
oxidase-conjugated goat anti-rabbit and goat anti-mouse secondary antibodies respectively
(Thermo Scientific, 1:2000). The enhanced chemiluminescence kit (GE Amersham) was ap-
plied to the blot, and bands were visualized by exposing the WB to X-ray film.
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Cell preparations and flow cytometry analysis
Peripheral blood was counted on a hematologic analyser (Sysmex KX-21N, Roche Diagnos-
tics). Spleens were weighed and crushed in FACS Buffer (PBS + 2% FBS) to make single-cell
suspensions. The bone marrow was recovered by flushing the femurs with FACS Buffer. The
bone marrow cell suspensions were then stained with anti-mouse antibodies. Antibodies
against murine CD2, CD3e, CD4, CD5, CD8a, CD11b, CD19, CD31, CD34, CD41, CD43,
CD44, CD45.1, CD45.2, CD51, B220, CD71, PDGFRα (CD140a), F4/80, Gr1, IgM, Mac1,
Sca1, and Ter119 were either biotinylated or conjugated with FITC, phycoerythrin, phycoery-
thrin-Cy5, peridinin chlorophyll protein-Cy5.5, phycoerythrin-Cy7, allophycocyanin, or allo-
phycocyanin Alexa 750 and were all obtained from eBioscience, Biolegend, BD Biosciences or
Life Technologies. Biotinylated antibodies were detected with streptavidin conjugated with
Alexa-Fluor 488 (Life Technologies) or Brilliant Violet 605 (eBiosciences) [27,53]. FACS data
was collected on an LSRIIFortessa (BD Biosciences) and analyzed with FlowJo software Ver-
sion 9.0 (Treestar).
Kaplan-Meier survival analysis and statistical analysis
Mice were monitored daily until they reached humane endpoint criteria. Once the criteria were
met, the mice were euthanised. The Kaplan-Meier survival plots, the Log-Rank statistical test
and the unpaird 1-tailed Student t-tests with were prepared using Prism 6.0 (Graphpad Soft-
ware). Census dates are the date of euthanasia of the tumor-bearing animal. All data is pre-
sented as mean ± S.E.M. A P value<0.05 was considered significant.
Supporting Information
S1 Fig. Histomorphometric analysis of Osx-Cre Recql4 animals.Histomorphometric analy-
sis of the secondary spongiosa of the proximal tibia from Osx-Cre Recql4+/+ and Recql4fl/fl
mice. (a) Trabecular bone volume (BV/TV), trabecular separation (Tb.Sp), trabecular number
(Tb.N), and trabecular thickness (Tb.Th). (b) Osteoid volume per unit bone volume (OV/BV),
osteoid surface per unit bone surface (OS/BS), osteoid thickness (O.Th). (c) Number of osteo-
blasts per unit bone perimeter (N.Ob/B.Pm), osteoclast surface per unit bone surface (Oc.S/
BS), and number of osteoclasts per unit bone perimeter (N.Oc/B.Pm). n = 5–7 per genotype;
Data presented as mean ± SEM.
(EPS)
S2 Fig. Deletion of Recql4 in osteoblasts does not affect hematopoiesis. (a) Total leukocyte
counts, platelet cell counts, red blood counts and hematocrit in peripheral blood of Osx-Cre
Recql4+/+ and Recql4fl/flmice. (b) Analysis of hematopoietic cell lineages from the bone marrow
of Osx-Cre Recql4+/+ and Recql4fl/flmice. (c) Gross weights and leukocyte counts from the
spleens of Osx-Cre Recql4+/+ and Recql4fl/flmice. For (a)-(c): n = 5 per genotype; Data pre-
sented as mean ± SEM.
(EPS)
S3 Fig. Genomic excision of Recql4 in 4OHT-treated R26Cre-ERT2 Recql4 primary osteo-
blastic cultures. Agarose gel photographs for the assessment of Recql4 genomic excision. 40ng
of genomic DNA from long-bone primary osteoblastic cells was obtained from several time-
points of 4OHT treatment, and subjected to PCR and gel electrophoresis. The quantification of
Recql4 genomic excision was presented in Fig 5B.
(EPS)
Recql4 Is Required for Normal Osteoblast Development
PLOS Genetics | DOI:10.1371/journal.pgen.1005160 April 10, 2015 21 / 25
S4 Fig. Assessing the effects of shRNA-mediated Recql4 knockdown in Kusa4b10 cells. (a)
Position of the various shRNAs that target the mouse Recql4 gene. Arrows in red depict the
binding region used for Recql4 qPCR primers. (b) Assessment of Recql4 transcript knockdown
in Kusa4b10 cells by qPCR. Relative gene expression levels were normalised to the expression
of Hprt. n = 3 biological replicates; Data presented as mean ± SEM.  P<0.05, compared with
shRNA-Luciferase, t-test. (c) Assessment of the effects of Recql4 knockdown on p21 and Noxa
expression in Kusa4b10 cells. Data are expressed as fold induction relative to transcript expres-
sion levels from shRNA-Luciferase cells. n = 3 biological replicates; Data presented as
mean ± SEM.  P<0.05,  P<0.01, compared with shRNA-Luciferase, t-test. (d) shRNA-Luci-
ferase and #5254 cells were cultured in 6-well plates for 3 days post-selection and subjected to
senescence-associated B-galactosidase staining. Light microscopic images were taken at 400X
magnification. (e) Transcript expression of osteo-lineage genes based on qPCR on shRNA-Lu-
ciferase and #5254 cells that were subjected to osteogenic differentiation. The relative gene ex-
pression is normalised to the expression of Hprt. Data presented as mean ± SEM from
biological replicates.
(EPS)
S5 Fig. Histology of primary OS tumours from Osx-Cre p53fl/fl Recql4mice. Paraffin sec-
tions were stained for H&E, and light microscopic images were taken at 100X magnification.
Scale bar: 200μm.
(TIF)
S1 Table. Summary of survival of Osx-Cre Recql4 and osteosarcoma models.
(DOCX)
S2 Table. Primers used for genomic DNA PCR.
(DOCX)
S3 Table. Primers used for qRT-PCR.
(DOCX)
S4 Table. Recql4 shRNA target sequences.
(DOCX)
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